CELZ News and Press, Creative Medical Technology Holdings Inc. From 02/08/23

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: Billion Photos / Shutterstock Creative Medical (NASDAQ: CELZ ) stock is rocketing higher on Wednesday thanks to clearance for a new clinical trial . That clearance comes from the FDA and covers CELZ-...

This week got off to a wild start, and Tuesday’s volatility from Fed Chair Jerome Powell’s commentary sent markets on a wild ride. While things have settled down a bit, there are still plenty of potential catalysts ahead this week. Many of those events center around central banker s...

Creative Medical Technology ( NASDAQ: CELZ ) said it received Institutional Review Board (IRB) approval to proceed with its phase 1/2 trial of cell therapy CELZ-201 to treat type 1 diabetes. The company noted that the U.S. Food and Drug Administration (FDA) had previously cl...

Creative Medical Technology Holdings Announces IRB Approval for FDA Cleared Phase 1/2 Clinical Trial of Novel Cell Therapy for the Treatment of Type 1 Diabetes PR Newswire Company reaches next clinical trial milestone for treatment of Type 1 Diabetes with the first novel all...

Creative Medical Technology ( NASDAQ: CELZ ) on Thursday said the U.S. FDA had cleared the company's investigational new drug application to initiate a clinical trial with its AlloStem cell therapy for type 1 diabetes. Shares of the micro-cap biotech gained 9.1% to $0....

Creative Medical Technology Holdings Announces FDA Clearance of Investigational New Drug (IND) Application for AlloStem™, a Novel Cell Therapy for the Treatment of Type 1 Diabetes PR Newswire AlloStem™ represents the first novel allogenic cellular ...

Creative Medical Technology Holdings Develops AlloStem™ Clinical Cell Line PR Newswire PHOENIX , Oct. 20, 2022 /PRNewswire/ -- Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) , a biotechnology company focused on a regenerative approac...

Creative Medical Technology Announces Peer Reviewed Publication of Positive Results for StemSpine® Study PR Newswire --Two-Year Follow-Up Results Confirm Significant Efficacy and No Serious Adverse Effects in Patients who Underwent the StemSpine® Procedure for ...

Creative Medical Technology Announces Positive Top-Line Results for OvaStem® Pilot Study PR Newswire Three-Year Follow Up Results Confirm Significant Efficacy and No Serious Adverse Effects in Patients receiving OvaStem® Procedure for Treating Primary Ovarian I...

3 Penny Stocks to Add to Your July Watchlist Finding penny stocks to buy in 2022 can be a challenge. The stock market has had several big runs since its low in March 2020, but, we have seen a major bearish rally as of late. And because of this, finding the best penny stocks to buy with ...